ArticleCureus2026
Endometriosis as a Silent Emerging Malignant Threat in Young Women: A Case Report of Rare Rapid Transformation of Abdominal Wall Endometriosis Into Mixed High-Grade Serous and Clear Cell Carcinoma One Year Following Cesarean Section.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abdominal wall endometriosis most commonly occurs in cesarean section (CS) scars. Although malignant transformation is rare, clear cell carcinoma (CCC) is the most commonly reported histological subtype. We present an unusual case of rapid malignant transformation into mixed high-grade serous and CCC within one year following CS. A 34-year-old para 1 woman presented with a two-month history of progressive shortness of breath, abdominal distension, abdominal pain, weight loss, and reduced appetite. Computed tomography (CT) demonstrated extensive peritoneal disease with bilateral ovarian lesions suspicious for advanced gynecological malignancy. She had a known history of endometriosis and had undergone a category 2 CS one year earlier, during which extensive pelvic endometriosis and decidualization were identified intraoperatively. Peritoneal biopsy performed at that time confirmed benign endometriosis without evidence of malignancy. Subsequent magnetic resonance imaging (MRI) demonstrated uterine scar endometriosis, abdominal wall scar endometriosis, and superficial ovarian endometriosis. Further investigations revealed malignant ascitic cytology consistent with metastatic high-grade serous carcinoma of gynecological origin. Diagnostic laparoscopy demonstrated extensive adhesions, ascites, diffuse peritoneal inflammatory disease, and complete obliteration of the pelvic anatomy. Histopathological analysis of biopsies obtained from the pelvic soft tissue, endometrioma cyst wall, and peritoneum confirmed mixed high-grade serous and CCC arising in a background of endometriosis. Following multidisciplinary team discussion, the patient underwent extensive cytoreductive surgery, including total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritonectomy, bilateral ureterolysis, pelvic lymph node excision, and infracolic omentectomy. She was subsequently diagnosed with stage IIIA2 ovarian mixed high-grade serous and CCC and commenced adjuvant chemotherapy with carboplatin and paclitaxel. This case highlights the potential for rare, aggressive, and rapidly progressive malignant transformation of endometriosis, including transformation into mixed histological subtypes, in young women of reproductive age. Clinicians should maintain a high index of suspicion in patients with endometriosis who present with new systemic symptoms, ascites, or rapidly progressive pelvic or abdominal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.